Stay updated on Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial page.

Latest updates to the Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page footer now displays Revision: v3.5.4, replacing the previous Revision: v3.5.3; this indicates a maintenance version update to the site and does not alter study content.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page’s revision/version label in the footer was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check32 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a minor update to the study record.SummaryDifference0.1%

- Check61 days agoChange DetectedAdded Hepatocellular carcinoma as the condition and the Genetic and Rare Diseases Information Center as a new resource. Updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check75 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2; no visible changes to the study details are evident.SummaryDifference0.1%

- Check97 days agoChange DetectedInvestigator list updated: Kannan Thanikachalam, MD added and Renuka Iyer removed. Page revised to version 3.4.2 on 2026-02-05.SummaryDifference0.3%

Stay in the know with updates to Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sorafenib and Pembrolizumab in Liver Cancer Clinical Trial page.